NSE: ACI· ChemicalsNot in Aug top-30Small cap

Archean Chemical Industries

Bromine cost-curve leader

Last close
₹490.60
29 Sept 2026 · reference
1D · 1M
+1.6% · +1.3%
price-only
Weight
0.6%
31 Jul 2026 · Aug rank —
Thesis review
8 Sep 2026
Why We Own, p66
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
What the business is

Approved description

Archean Chemical is India's largest producer of bromine and industrial salt from brine at Hajipir, Gujarat (Rann of Kutch), with ~78% of revenue exported; FY26 revenue Rs 1,108 cr split industrial salt Rs 729 cr and bromine Rs 308 cr. It is building sulphate of potash (SOP), bromine derivatives (Acume, EBITDA-positive for the first time in Q1FY27), zinc-bromide energy storage, and a USD 250 mn silicon-carbide semiconductor fab/packaging unit (SiCSem, Odisha; 60,000 wafers and 96 mn packaging units/yr; partners Clas-SiC UK, Aixtron, IIT Bhubaneswar) approved under the India Semiconductor Mission.

Why we own it · 5 approved reasons
  1. 01Bromine cycle turning after three weak years: Q1FY27 bromine realisations +50% YoY, volumes at a five-quarter high; China bromine +35% in Q1CY26 to ~USD 4,900/t (Jun-2026) before easing to USD 4,347/t (Jul-2026) - still far above the 2024-25 trough.
  2. 02Operating leverage on a low base: FY26 EBITDA Rs 239 cr (22% margin) vs Rs 463 cr (35%) in FY24; ICICI Sec sees >50% EBITDA CAGR FY26-28 as bromine run-rate rises to 20-24 kt and freight/fuel costs stabilise.
  3. 03New products moving from cost to profit: Acume bromine derivatives EBITDA-positive for the first time in Q1FY27 (Rs 1.9 cr vs Rs -2.7 cr), SOP phase-2 trials by Q3FY27, zinc-bromide off-grid storage.
  4. 04Optionality in SiC semiconductors: USD 250 mn SiCSem fab in Odisha under ISM fiscal support (agreement 11-May-2026), 60,000 wafers/yr, revenue from FY29 - not in broker estimates.
  5. 05Low leverage and export-led: borrowings Rs 466 cr vs equity Rs 1,935 cr; ~78% exports; working-capital days improved from 49.5 to 10.8.
Full thesis, sizing and review history →
Price

Reference close, with results-period markers

ACI
Close as of 29 Sept 2026
  1. 1Q Sep-25 end · 30 Sept 2025
  2. 2Q Dec-25 end · 31 Dec 2025
  3. 3Q Mar-26 end · 31 Mar 2026
  4. 4Q Jun-26 end · 30 Jun 2026
Yahoo Finance chart API (unlicensed reference data; not for redistribution). Price-only series (split-adjusted; dividends excluded). Gaps are non-trading days.
1D
+1.6%
28 Sept 2026
1W
+5.9%
22 Sept 2026
1M
+1.3%
28 Aug 2026
3M
−5.9%
29 Jun 2026
6M
−19.4%
27 Mar 2026
1Y
−27.9%
29 Sept 2025
Buoyant Screener

Quality score, technicals and Buoyant Score

Value it →

Computing the scorecard…

Results centre

Latest quarter · Q Jun-26

Latest quarter versus prior year and prior quarter
Line (₹ cr)Q Jun-26YoYQoQ
Net Sales327+12.0%+8.6%
Operating Profit67−13.9%+53.9%
Net Profit31−23.7%+128.6%
Implication for thesisBroadly unchanged · per 8 Sep 2026 reviewQ1FY27 (Jun-26): revenue 333 (+10.7% YoY), PAT 30 (-25.0%)

Reported vs internal estimate: internal quarterly estimates are not in the supplied package; consensus feed not licensed. YoY/QoQ per PRD §12.5 (transitions, not %, on non-positive bases).

Key facts

Position and valuation context

0.6%
Weight, 31 Jul 2026
Aug rank — · —
₹6,928 cr
Market cap, July 2026 research sheet
Tijori latest: 5,719 Cr
44.2x
P/E FY27E · Buoyant
FY28E 34.6x
7.9%
ROE FY27E · Buoyant
FY28E 9.2%
59.1x
P/E trailing (Tijori)
5.52%
ROE latest FY (Tijori)
ROCE 7.07%

Commodity/cyclical preset: volumes, realisations, unit cost, mid-cycle earnings, leverage.

Investment case and valuation

Valuation range

No headline target on this page; the book quotes the thesis and the risk rather than a target.

₹499
Price (2026-09-07)
44.2x / 34.6x
FY27E / FY28E P/E (Buoyant sheet)
7.9%
FY27E ROE (Buoyant sheet)
63.6x
Trailing P/E
3.2x
Price / book
n.a.
EPS CAGR FY26–28E
Assumptions, sensitivity, scenarios →
Next catalysts · material risks

What we watch

Catalysts
  • Q2FY27 results (Nov-2026): bromine volume run-rate progressing toward 20-24 kt and salt pricing stabilisation guided for H2FY27.
  • SOP phase-2 commissioning by Q3FY27 and continued Acume derivatives profitability.
  • SiCSem fab milestones (equipment orders with Aixtron, Clas-SiC integration) and any ISM disbursement news.
Key risks
  • Bromine price volatility: prices already fell 11% QoQ in Jul-2026 as Chinese supply recovered; FY26 bromine revenue fell 13% and Q4FY26 had technical downtime.
  • Capital intensity and execution: borrowings up from Rs 98 cr (FY24) to Rs 466 cr (FY26) funding SOP, derivatives and the USD 250 mn SiC fab - a technology the company has no track record in; interest/depreciation already dragged Q1FY27 PAT -25%.
  • Salt business (66% of FY26 revenue) faces weak pricing and freight sensitivity; ROE only 5.4% in FY26 (3-yr 11%).
Sources: · fundamentals Tijori Finance (company filings), pulled locally via MCP batch; not licensed for redistribution · prices Yahoo Finance chart API (unlicensed reference data; not for redistribution).